U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H18N8O7S3
Molecular Weight 554.5839
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFTRIAXONE

SMILES

Cn1c(nc(=O)c(=O)[nH]1)SCC2=C(C(=O)O)N3C(=O)[C@]([H])([C@@]3([H])SC2)N=C(/C(=N\OC)/c4csc(=N)[nH]4)O

InChI

InChIKey=VAAUVRVFOQPIGI-SPQHTLEESA-N
InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H18N8O7S3
Molecular Weight 554.5839
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/pro/ceftriaxone.html | http://www.rxlist.com/ceftriaxone-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/6967869

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

Originator

Curator's Comment:: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9NSA0
Gene ID: 55867.0
Gene Symbol: SLC22A11
Target Organism: Homo sapiens (Human)
2.38 µM [Ki]
Target ID: Q4U2R8|||Q9NQC2
Gene ID: 9356.0
Gene Symbol: SLC22A6
Target Organism: Homo sapiens (Human)
0.23 µM [Ki]
Target ID: Q8TCC7
Gene ID: 9376.0
Gene Symbol: SLC22A8
Target Organism: Homo sapiens (Human)
4.39 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Curative
CEFTRIAXONE

Approved Use

INDICATIONS & USAGE Before instituting treatment with ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection, USP and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection, USP may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection, USP has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, USP provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Launch Date

1.06487998E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
82 μg/mL
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTRIAXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
478 μg × h/mL
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTRIAXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.7 h
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTRIAXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
0.5 g single, intravenous
dose: 0.5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFTRIAXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 1 times / day single, intravenous
Studied dose
Dose: 2 g, 1 times / day
Route: intravenous
Route: single
Dose: 2 g, 1 times / day
Co-administed with::
Dexamethasone
Sources:
unhealthy, 4 years
n = 1
Health Status: unhealthy
Condition: Bronchitis
Age Group: 4 years
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactic shock...
Other AEs:
Anaphylactic shock (grade 5)
Sources:
0.3 g 1 times / day single, intravenous
Studied dose
Dose: 0.3 g, 1 times / day
Route: intravenous
Route: single
Dose: 0.3 g, 1 times / day
Co-administed with::
Vitamin C
Vitamin B6
Sources:
unhealthy, 9 days
n = 1
Health Status: unhealthy
Condition: Hyperbilirubinemia
Age Group: 9 days
Sex: M
Population Size: 1
Sources:
Other AEs: Anaphylactic shock...
Other AEs:
Anaphylactic shock (grade 5)
Sources:
2 g 2 times / day multiple, intravenous
Recommended
Dose: 2 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 2 times / day
Sources:
unhealthy, mean age 54 years
n = 22
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: mean age 54 years
Sex: M+F
Population Size: 22
Sources:
Disc. AE: Cholelithiasis, Pulmonary edema...
AEs leading to
discontinuation/dose reduction:
Cholelithiasis
Pulmonary edema
Sources:
3.5 g 2 times / day multiple, intravenous (median)
Highest studied dose
Dose: 3.5 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 3.5 g, 2 times / day
Sources:
unhealthy, median age 59 years
n = 198
Health Status: unhealthy
Condition: CNS infection
Age Group: median age 59 years
Sex: M+F
Population Size: 198
Sources:
Other AEs: Thrombocytopenia, Neutropenia...
Other AEs:
Thrombocytopenia (grade 3)
Neutropenia (grade 3)
Sources:
7 g 2 times / day multiple, intravenous (median)
Highest studied dose
Dose: 7 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 7 g, 2 times / day
Sources:
unhealthy, median age 59 years
n = 198
Health Status: unhealthy
Condition: CNS infection
Age Group: median age 59 years
Sex: M+F
Population Size: 198
Sources:
Other AEs: Hallucination...
Other AEs:
Hallucination (grade 2)
Sources:
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Other AEs: Dyspnea, Cholelithiasis...
Other AEs:
Dyspnea (serious, 74 patients)
Cholelithiasis (serious, 28 patients)
Dysphagia (serious, 4 patients)
Cholecystitis (serious, 5 patients)
Diarrhea (serious, 3 patients)
Dehydration (serious, 2 patients)
Hypoxia (serious, 2 patients)
Pneumothorax (serious, 2 patients)
Atelectasis (serious, 1 patient)
Cognitive disturbance (serious, 1 patient)
Colitis (serious, 1 patient)
Confusion (serious, 1 patient)
Cough (serious, 1 patient)
Vomiting (serious, 1 patient)
Pancreatitis (serious, 7 patients)
Diarrhea (below serious, 152 patients)
Cholelithiasis (below serious, 158 patients)
Desquamation (below serious, 92 patients)
Constipation (below serious, 66 patients)
Nausea (below serious, 64 patients)
Insomnia (below serious, 40 patients)
Cough (below serious, 41 patient)
Fracture (below serious, 24 patients)
Vomiting (below serious, 24 patients)
Hypertension (below serious, 16 patients)
Lymphopenia (below serious, 20 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anaphylactic shock grade 5
2 g 1 times / day single, intravenous
Studied dose
Dose: 2 g, 1 times / day
Route: intravenous
Route: single
Dose: 2 g, 1 times / day
Co-administed with::
Dexamethasone
Sources:
unhealthy, 4 years
n = 1
Health Status: unhealthy
Condition: Bronchitis
Age Group: 4 years
Sex: M
Population Size: 1
Sources:
Anaphylactic shock grade 5
0.3 g 1 times / day single, intravenous
Studied dose
Dose: 0.3 g, 1 times / day
Route: intravenous
Route: single
Dose: 0.3 g, 1 times / day
Co-administed with::
Vitamin C
Vitamin B6
Sources:
unhealthy, 9 days
n = 1
Health Status: unhealthy
Condition: Hyperbilirubinemia
Age Group: 9 days
Sex: M
Population Size: 1
Sources:
Cholelithiasis Disc. AE
2 g 2 times / day multiple, intravenous
Recommended
Dose: 2 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 2 times / day
Sources:
unhealthy, mean age 54 years
n = 22
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: mean age 54 years
Sex: M+F
Population Size: 22
Sources:
Pulmonary edema Disc. AE
2 g 2 times / day multiple, intravenous
Recommended
Dose: 2 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 2 times / day
Sources:
unhealthy, mean age 54 years
n = 22
Health Status: unhealthy
Condition: amyotrophic lateral sclerosis
Age Group: mean age 54 years
Sex: M+F
Population Size: 22
Sources:
Neutropenia grade 3
3.5 g 2 times / day multiple, intravenous (median)
Highest studied dose
Dose: 3.5 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 3.5 g, 2 times / day
Sources:
unhealthy, median age 59 years
n = 198
Health Status: unhealthy
Condition: CNS infection
Age Group: median age 59 years
Sex: M+F
Population Size: 198
Sources:
Thrombocytopenia grade 3
3.5 g 2 times / day multiple, intravenous (median)
Highest studied dose
Dose: 3.5 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 3.5 g, 2 times / day
Sources:
unhealthy, median age 59 years
n = 198
Health Status: unhealthy
Condition: CNS infection
Age Group: median age 59 years
Sex: M+F
Population Size: 198
Sources:
Hallucination grade 2
7 g 2 times / day multiple, intravenous (median)
Highest studied dose
Dose: 7 g, 2 times / day
Route: intravenous
Route: multiple
Dose: 7 g, 2 times / day
Sources:
unhealthy, median age 59 years
n = 198
Health Status: unhealthy
Condition: CNS infection
Age Group: median age 59 years
Sex: M+F
Population Size: 198
Sources:
Diarrhea below serious, 152 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cholelithiasis below serious, 158 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Hypertension below serious, 16 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Lymphopenia below serious, 20 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Fracture below serious, 24 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Vomiting below serious, 24 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Insomnia below serious, 40 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cough below serious, 41 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Nausea below serious, 64 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Constipation below serious, 66 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Desquamation below serious, 92 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Atelectasis serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cognitive disturbance serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Colitis serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Confusion serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cough serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Vomiting serious, 1 patient
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Dehydration serious, 2 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Hypoxia serious, 2 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Pneumothorax serious, 2 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cholelithiasis serious, 28 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Diarrhea serious, 3 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Dysphagia serious, 4 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Cholecystitis serious, 5 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Pancreatitis serious, 7 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
Dyspnea serious, 74 patients
2 g 2 times / day steady, intravenous
Dose: 2 g, 2 times / day
Route: intravenous
Route: steady
Dose: 2 g, 2 times / day
Sources:
unhealthy
n = 340
Health Status: unhealthy
Condition: Amyotrophic Lateral Sclerosis
Population Size: 340
Sources:
PubMed

PubMed

TitleDatePubMed
Ceftriaxone-associated nephrolithiasis.
1990
Ceftriaxone-induced cholelithiasis.
1991 Nov 1
Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis.
1991 Sep
Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy.
1992 Aug
Ceftriaxone-associated gallbladder pseudolithiasis: report of one case.
2004 Sep-Oct
Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children.
2005 Feb
[Pseudotumor cerebri probably due to ceftriaxone].
2005 Mar
Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease.
2005 May
Ceftriaxone-induced symptomatic pseudolithiasis mimicking ICP elevation.
2005 May
[Cholelithiasis associated with the use of ceftriaxone].
2005 Nov-Dec
Nephrolithiasis in a child with acute pyelonephritis. Ceftriaxone-induced nephrolithiasis and biliary pseudolithiasis.
2005 Oct
Ceftriaxone-associated biliary pseudolithiasis in children.
2006 Jun
Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.
2006 Jun
Ceftriaxone-related hemolysis and acute renal failure.
2006 May
Delirium induced by clarithromycin in a patient with community-acquired pneumonia.
2006 Sep
One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.
2007 Apr
Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice.
2007 Jan
[Serious side effects of frequently used antibiotics in childhood: biliary sludge or stones induced by ceftriaxone and thrombocytopenia induced by co-trimoxazole].
2007 Jun 9
Ceftriaxone associated nephrolithiasis: a prospective study in 284 children.
2007 May
Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: case series and review of the literature.
2007 Oct
Biliary precipitation during ceftriaxone therapy: frequency and risk factors.
2007 Oct-Dec
Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity.
2008
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
2008 Apr 15
The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians.
2008 Apr 28
Ceftriaxone induced hemolysis complicated by acute renal failure.
2008 Jan
Intravascular haemolysis in a patient on ceftriaxone with demonstration of anticeftriaxone antibodies.
2008 Jun
Hemolytic anemia from ceftriaxone in an elderly patient: a case report.
2008 Oct
Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis.
2008 Sep
Acute cholecystitis caused by ceftriaxone stones in an adult.
2009
Normal pressure hydrocephalus or neuroborreliosis?
2009
[Acute pancreatitis associated with the administration of ceftriaxone in an adult patient].
2009 Apr
Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.
2009 Apr
Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection.
2009 Feb
Fever, pain, and a limp: a case of a psoas and spinal epidural abscess caused by methicillin-resistant Staphylococcus aureus in a diabetic patient.
2009 Jan
[When an antibiotic becomes toxic].
2009 Jan
Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis.
2009 Jul
Adverse drug reactions in medical intensive care unit of a tertiary care hospital.
2009 Jul
Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats.
2009 Jul 22
Ceftriaxone-induced toxic hepatitis.
2009 Jun 7
Ceftriaxone-vancomycin drug toxicity reduction by VRP 1020 in Mus musculus mice.
2009 May
Severe ceftriaxone-induced hemolysis complicated by diffuse cerebral ischemia in a child with sickle cell disease.
2009 Nov
Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in Chinese children.
2010
Transfusion med illustrated: Ceftriaxone-induced acute hemolytic anemia.
2010 Aug
Ceftriaxone-associated cholelithiasis: 30 min drip infusion versus bolus injection.
2010 Dec
Accidental induced seizures in three cynomologus macaques following administration of ceftriaxone dissolved in 1% lidocaine diluent.
2010 Jan
Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking.
2010 Jan 1
[Reversible ceftriaxone-associated biliary pseudolithiasis in three children with renal diseases].
2010 Mar
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
2010 May
Reversible choreoathetosis after the administration of ceftriaxone sodium in patients with end-stage renal disease.
2010 Nov
Epidural abscess caused by community-associated methicillin-resistant Staphylococcus aureus strain USA300 in Japan.
2010 Oct
Patents

Sample Use Guides

The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams. For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended.
Route of Administration: Other
ceftriaxone MIC cutoff of 8 μg/ml against E. coli, Klebsiella spp., and P. mirabilis is an excellent predictor of extended-spectrum β-lactamase (ESBL) production, with a positive predictive value and negative predictive value approaching 100% and 99.5%, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:57:19 UTC 2021
Edited
by admin
on Sat Jun 26 01:57:19 UTC 2021
Record UNII
75J73V1629
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFTRIAXONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-(((1,2,5,6-TETRAHYDRO-2-METHYL-5,6-DIOXO-1,2,4-TRIAZIN-3-YL)THIO)METHYL)-, (6R-(6.ALPHA.,7.BETA.(Z)))-
Common Name English
CEFTRIAXON
Common Name English
CEFTRIAXONE [INN]
Common Name English
CEFTRIAXONE [MI]
Common Name English
CEFTRIAXONE [VANDF]
Common Name English
CEFTRIAXONE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01DD04
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
WHO-ATC J01DD54
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
LIVERTOX 174
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
WHO-VATC QJ01DD54
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
WHO-ATC J01DD63
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NCI_THESAURUS C357
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000175488
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
WHO-ATC J01DD04
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
EU-Orphan Drug EU/3/14/1425
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
Code System Code Type Description
PUBCHEM
5479530
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
WIKIPEDIA
CEFTRIAXONE
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
FDA UNII
75J73V1629
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
NCI_THESAURUS
C62020
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
DRUG BANK
DB01212
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
RXCUI
2193
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M3225
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
277-405-6
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
IUPHAR
5326
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
LACTMED
Ceftriaxone
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
CAS
73384-59-5
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
EVMPD
SUB07431MIG
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
EPA CompTox
73384-59-5
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
MESH
D002443
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
INN
4923
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL161
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
DRUG CENTRAL
564
Created by admin on Sat Jun 26 01:57:19 UTC 2021 , Edited by admin on Sat Jun 26 01:57:19 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
INHIBITOR -> TARGET
in vivo mechanism of action of ribaxamase, degradation of ?-lactam antibiotics in the human intestine
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC